Introducing too many secondary conditions in any trial is an invitation for the drug to fail safety and/or efficacy due to increased demands on both. And as we all know, a huge fraction of drugs fail in phase 3 already. Raising the bar further, without great care, will serve neither patients nor business.
It'd also be a good starting point to be more concrete in your ambitions. What version of C is your preferred starting point, the basis for your "Better C"?
I'd also suggest the name "Dependable C" confuses readers about your objective. You don't seek reliability but a return to C's simpler roots. All the more reason to choose a recognized historical version of C as your baseline and call it something like "Essential C".